Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Mega Genomics Limited ( (HK:6667) ).
Mega Genomics Limited reported that, despite the ongoing suspension of trading in its shares, its core genetic testing and cancer screening operations in China have continued largely as normal, with extensive collaboration across over 340 cities and more than 25 million tests completed to date. The company has completed an independent forensic investigation whose findings satisfied both its Investigation Committee and Board, and it has submitted a preliminary internal control review report to the Hong Kong Stock Exchange, signaling progress toward meeting resumption requirements and addressing governance and control issues that are critical for investor confidence and potential trading reinstatement.
More about Mega Genomics Limited
Mega Genomics Limited is a leading genetic testing platform company in China, primarily providing consumer genetic testing and cancer screening services. The group collaborates with healthcare institutions in more than 340 cities nationwide and has conducted over 25 million genetic tests, indicating a broad market presence in China’s medical and consumer genomics sectors.
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.61B
Learn more about 6667 stock on TipRanks’ Stock Analysis page.